- Home
- NGEN vs ABEO Comparison
NGEN vs ABEO Comparison
Compare NGEN & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NGEN | ABEO |
|---|---|---|
| Founded | 2017 | 1974 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 317.6M | 280.2M |
| IPO Year | N/A | 1980 |
Fundamental Metrics
Financial Performance| Metric | NGEN | ABEO |
|---|---|---|
| Price | $4.04 | $5.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $18.20 |
| AVG Volume (30 Days) | 163.1K | ★ 1.2M |
| Earning Date | 04-02-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 1.29 |
| Revenue | N/A | ★ $400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,589.77 |
| P/E Ratio | ★ N/A | $3.99 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.50 | $3.93 |
| 52 Week High | $6.30 | $7.54 |
Technical Indicators
Market Signals| Indicator | NGEN | ABEO |
|---|---|---|
| Relative Strength Index (RSI) | 27.10 | 50.46 |
| Support Level | $3.80 | $4.90 |
| Resistance Level | $4.34 | $5.42 |
| Average True Range (ATR) | 0.36 | 0.24 |
| MACD | -0.07 | -0.01 |
| Stochastic Oscillator | 18.02 | 58.27 |
Price Performance
Historical ComparisonAbout NGEN NervGen Pharma Corp. Common stock
NervGen Pharma Corp is a clinical-stage biotech company. The company's principal business activity is the discovery, development, and commercialization of pharmaceutical treatments that enable the nervous system to repair itself following damage, whether due to injury or disease. The company's initial target indication is spinal cord injury. The company's pipeline products include NVG-291 and NVG-300.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.